• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

    1/30/23 2:53:12 PM ET
    $CLGN
    Industrial Specialties
    Health Care
    Get the next $CLGN alert in real time by email
    SC 13G/A 1 clgn2022.htm IMVA13G_CLGN12.31.2022
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    
    SCHEDULE 13G
    
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    
    COLLPLANT BIOTECHNOLOGIES LTD.
    
    M2R51X116
    
    December 31, 2022
    
    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    
    [ X ]		Rule 13d-1 (b)
    [   ]    	Rule 13d-1 (c)
    [   ]    	Rule 13d-1 (d)
    
    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that Section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    
    CUSIP No. M2R51X116
    
    1. Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons
    
    Investment Management of Virginia, LLC
    54-1994290
    
    2. Check the Appropriate Box if a Member of a Group
    (a) __________
    (b) __________
    
    3. SEC Use Only
    
    4. Citizenship or Place of Organization
    
    Virginia United States
    
    Number of Shares Beneficially Owned by Each Reporting Person With:
    
    5.  Sole Voting Power
    
    541,411
    
    6.  Shared Voting Power
    
    3,000
    
    7.  Sole Dispositive Power
    
    463,899
    
    8.  Shared Dispositive Power
    
    80,512
    
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    
    544,411
    
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares*
    
    
    11.  Percent of Class Represented by Amount in Row (9)
    
    4.9%
    
    12.  Type of Reporting Person*
    
    IA
    
    
    
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    
    SCHEDULE 13G
    
    Under the Securities Exchange Act of 1934
    
    
    Item 1.
    
    (a) Name of Issuer:
    
    COLLPLANT BIOTECHNOLOGIES LTD.
    
    (b) Address of Issuer's Principal Executive Offices:
    
    4 Oppenheimer St, Weizmann Science Park
    Rehovot 7670104, Israel
    
    Item 2.
    
    (a) Name of Person Filing:
    
    Investment Management of Virginia, LLC
    
    (b) Address of Principal Business Office or, if none, Residence:
    
    7231 Forest Avenue, Suite 204
    Richmond, VA 23226
    
    (c) Citizenship:
    
    Virginia United States
    
    (d) Title of Class of Securities:
    
    American Depositary Shares
    
    (e) CUSIP Number
    
    M2R51X116
    
    Item 3.	If this statement is filed pursuant to Section 240.13d-1(b) or
    240.13-2(b) or (c), check whether the person filing is a:
    
    (a) [  ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
    
    (b) [  ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    
    (c) [  ]	Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    
    (d) [  ]	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    
    (e) [ X]	An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
    
    (f) [  ]	An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
    
    (g) [  ]	A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
    
    (h) [  ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12  U.S.C. 1813);
    
    (i) [  ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    
    (j) [  ]	Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).
    
    
    Item 4.	Ownership
    
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    
    (a) Amount beneficially owned:   544,411
    
    (b) Percent of class:   4.9%
    
    (c) Number of shares as to which the person has:
    
    (i) Sole power to vote or to direct the vote:   541,411
    
    (ii) Shared power to vote or to direct the vote:   3,000
    
    (iii) Sole power to dispose or to direct the disposition of:   463,899
    
    (iv) Shared power to dispose or to direct the disposition of:   80,512
    
    Item 5.	Ownership of Five Percent or Less of a Class
    
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
    [X].
    
    Item 6.	Ownership of More than Five Percent on Behalf of Another Person
    
    Not applicable
    
    Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    
    Not applicable
    
    Item 8.	Identification and Classification of Members of the Group
    
    Not applicable
    
    Item 9.	Notice of Dissolution of Group
    
    Not Applicable
    
    Item 10. Certification
    
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11.
    
    
    SIGNATURE
    
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    
    January 30, 2023
    Date
    
    /s/  John H. Bocock
    Signature
    John H. Bocock / Chief Compliance Officer, Chairman, Member
    Name / Title
    
    
    
    Get the next $CLGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLGN

    DatePrice TargetRatingAnalyst
    2/17/2023$22.75Buy
    Alliance Global Partners
    More analyst ratings

    $CLGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies

      CollPlant's novel rhCollagen BioInks are an available solution aligned with FDA's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates REHOVOT, Israel, April 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, commented today, following the United States Food and Drug Administration (FDA)'s groundbreaking step announced last week to advance public health by replacing animal testing i

      4/15/25 8:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp

      3/26/25 8:00:00 AM ET
      $CLGN
      $SSYS
      Industrial Specialties
      Health Care
      Computer peripheral equipment
      Technology
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

      Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel, March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its financial results and corporate updates on Wednesday, March 26th at 10:

      3/19/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

      Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

      5/23/22 8:00:00 AM ET
      $CFRX
      $CLGN
      $ENLV
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • RION Appoints Alisa Lask as Chief Commercial Officer

      - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

      1/14/22 9:00:00 AM ET
      $CLGN
      $NEPH
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors

      REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlant Board. "Alisa brings a strong background in global strategy and marketing that will be very helpful to maximizing the v

      8/19/21 8:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    SEC Filings

    See more
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      4/15/25 8:14:46 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 20-F filed by CollPlant Biotechnologies Ltd

      20-F - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      3/26/25 10:13:19 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      3/26/25 9:52:36 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      2/13/24 4:01:04 PM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      1/25/24 3:27:05 PM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      7/24/23 6:27:46 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Financials

    Live finance-specific insights

    See more
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp

      3/26/25 8:00:00 AM ET
      $CLGN
      $SSYS
      Industrial Specialties
      Health Care
      Computer peripheral equipment
      Technology
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

      Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel, March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its financial results and corporate updates on Wednesday, March 26th at 10:

      3/19/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

      -Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3.0 billion market opportunity -Cash and cash equivalents balance as of September 30, 2024 was $15.4 million -Conference call to be held today at 10:00 a.m. U.S. EDT – REHOVOT, Israel, Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration

      11/27/24 7:00:00 AM ET
      $CLGN
      $SSYS
      Industrial Specialties
      Health Care
      Computer peripheral equipment
      Technology

    $CLGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on CollPlant with a new price target

      Alliance Global Partners initiated coverage of CollPlant with a rating of Buy and set a new price target of $22.75

      2/17/23 8:30:35 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. reiterated coverage on CollPlant Biotechnologies with a new price target

      HC Wainwright & Co. reiterated coverage of CollPlant Biotechnologies with a rating of Buy and set a new price target of $26.00 from $13.00 previously

      2/9/21 6:08:53 AM ET
      $CLGN
      Industrial Specialties
      Health Care